The global retinal disease therapeutics market, valued at USD 11,044.2 million in 2018, is anticipated to grow to USD 21,318.0 million by 2026, reflecting a compound annual growth rate (CAGR) of 8.6%. In 2018, North America led the global market, accounting for 36.6% of the total share.

The retinal disease therapeutics market focuses on the development and commercialization of treatments for various retinal disorders, including age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. These conditions can lead to vision impairment or blindness if left untreated, making early diagnosis and effective therapies crucial. The market encompasses a range of treatment options such as anti-VEGF drugs, corticosteroids, laser therapies, and emerging gene and cell-based therapies. Ongoing research, coupled with advancements in drug delivery systems and imaging technologies, continues to drive innovation in the field. As the global burden of retinal diseases increases, the demand for effective and accessible therapeutics is expected to grow significantly.

Continue reading for more details:

https://www.fortunebusinessinsights.com/industry-reports/retinal-disease-therapeutics-market-100311

Retinal Disease Therapeutics Market Overview & Key Insights

Market Size & Forecast:
The global retinal disease therapeutics market was valued at USD 11,044.2 million in 2018 and is projected to reach USD 21,318.0 million by 2026, growing at a CAGR of 8.6% during the forecast period from 2018 to 2026.

Market Share Insights:

• Regional Landscape: In 2018, North America led the market with a 36.6% share, fueled by early regulatory approvals of innovative anti-VEGF therapies, a strong ophthalmic drug development pipeline, and high diagnosis and treatment rates across the region.

• By Disease Indication: Macular degeneration accounted for the largest share at 42.9% in 2018 and is expected to maintain its dominance through 2026. This is primarily attributed to the widespread prevalence of age-related macular degeneration (AMD) and the increasing availability of advanced diagnostic technologies.

Key Country Highlights:

• Japan: An aging population and proactive government-led awareness campaigns are encouraging the use of retinal therapies, particularly anti-VEGF treatments.

• United States: Market growth is driven by the widespread use and approval of therapies such as Eylea, Lucentis, and Avastin. High incidence rates of diabetic retinopathy and AMD continue to elevate the demand for treatment options.

• China: A surge in diabetes cases and increasing efforts for early detection of eye diseases are supporting the rapid expansion of the retinal therapeutics market.

• Europe: With over 34 million individuals affected by AMD across the EU, the region remains a key market. Strong reimbursement systems and well-established healthcare infrastructure are accelerating the adoption of novel therapies.

Market Segmentation

• By disease indication, the retinal disease therapeutics market is segmented into age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion, and others.

• Macular degeneration is expected to hold the dominant share due to high global prevalence and increased uptake of anti-VEGF treatments.

• By treatment type, the market includes anti-VEGF agents, corticosteroids, laser therapy, and gene therapies.

• The anti-VEGF segment accounts for the largest share in the retinal disease therapeutics market, driven by widespread clinical use and effectiveness.

• Distribution channels include hospital pharmacies, retail pharmacies, and online providers, with hospital pharmacies capturing the bulk of the share due to high patient footfall.

Key Companies Covered In The Report:

• Merck & Co., Inc.

• Novartis AG

• Allergan plc

• Hoffmann-La Roche AG

• Regeneron Pharmaceuticals, Inc.

• Santen Pharmaceutical Co., Ltd.

Market Growth

• The retinal disease therapeutics market is witnessing steady expansion due to the increasing prevalence of age-related macular degeneration (AMD), diabetic retinopathy, and other retinal disorders.

• Continuous advancements in biologics and gene therapy are accelerating innovation within the retinal disease therapeutics market.

• Rising awareness regarding early diagnosis and timely intervention is further fueling the growth trajectory of the retinal disease therapeutics market.

• Growing elderly populations globally, particularly in developed countries, are significantly contributing to market demand.

• Favorable regulatory support and expedited approvals for breakthrough therapies are strengthening the overall retinal disease therapeutics market outlook.

Restraining Factors

• High treatment costs and limited access to advanced therapies in low-income regions hinder the growth of the retinal disease therapeutics market.

• Stringent regulatory approval timelines for novel biologics can delay product launches.

• Lack of awareness and poor diagnosis rates in rural areas negatively impact therapeutic adoption.

• Side effects associated with intravitreal injections may reduce patient compliance and adherence.

• Dependence on a limited number of blockbuster drugs poses risks in terms of pricing pressure and generic erosion.

Regional Analysis:

Regionally, North America holds a significant share of the retinal disease therapeutics market, attributed to advanced healthcare infrastructure, strong R&D investments, and high disease awareness. Europe follows closely, benefiting from favorable reimbursement policies and a growing geriatric population. The Asia-Pacific region is anticipated to witness the fastest growth due to increasing healthcare expenditure, rising diabetes prevalence, and expanding access to treatment options.